Literature DB >> 27271928

Laparoscopic Right Hepatectomy for Cirrhotic Patients: Takasaki's Hilar Control and Caudal Approach.

Jaime Arthur Pirola Krüger1,2, Gilton Marques Fonseca3, Fabrício Ferreira Coelho3, Vagner Jeismann3,4, Paulo Herman3.   

Abstract

BACKGROUND: Cirrhotic patients bearing hepatocellular carcinomas (HCC) derive benefits from laparoscopic hepatectomy1 - 6 such as reduced bleeding, less overall and liver-specific complications, and fewer adhesions in the case of future reoperation or transplantation.7 - 10 Bleeding is concerning in the setting of cirrhosis,11 - 15 and adequate inflow control reduces blood loss. The caudal approach is the laparoscopic counterpart of the anterior approach to open surgery. It implies in parenchymal transection initiated from the visceral surface of the liver after limited hepatic mobilization, reducing the risk of increased circulating tumoral cells.16 - 18 Venous outflow transection and completion of ligament mobilization are left as last steps.
METHODS: A 46 years-old-male with hepatitis C virus and alcoholic cirrhosis was diagnosed with a 4-cm HCC (right hepatic lobe). Expected future liver remnant was 45 % of his total liver volume. A totally laparoscopic right hepatectomy was performed using six ports, and the specimen was removed through a Pfannenstiel auxiliary incision. A 10-mm 30° scope was used. The pneumoperitoneum pressure was set to 12 mmHg. The right hepatic pedicle, the caudate lobe, and the major hepatic veins were managed with laparoscopic vascular staplers.
RESULTS: Surgery was performed with limited liver mobilization and en bloc extrafascial right pedicle control (Takasaki's technique),19 followed by caudal parenchymal transection along the paracaval plane. The operative time was 450 min, and the estimated blood loss was 800 ml (no transfusion was required).
CONCLUSION: The laparoscopic Takasaki technique and caudal approach are feasible procedures in the setting of cirrhosis, resulting in an oncologic adequate intervention with less morbidity.

Entities:  

Mesh:

Year:  2016        PMID: 27271928     DOI: 10.1245/s10434-016-5288-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  5 in total

1.  Perioperative and long-term outcomes of laparoscopic versus open liver resection for hepatocellular carcinoma with well-preserved liver function and cirrhotic background: a propensity score matching study.

Authors:  Xinqiang Wu; Zejian Huang; Wan Yee Lau; Wenda Li; Pai Lin; Lei Zhang; Yajin Chen
Journal:  Surg Endosc       Date:  2018-07-09       Impact factor: 4.584

2.  Recurrence of Hepatocellular Carcinoma After Laparoscopic Hepatectomy: Risk Factors and Treatment Strategies.

Authors:  Xiaodong Xu; Jiahui Chen; Feiran Wang; Qinggan Ni; Ullah Naimat; Zhong Chen
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2017-03-22       Impact factor: 1.878

3.  Laparoscopic liver resection of hepatocellular carcinoma located in unfavorable segments: a propensity score-matched analysis from the I Go MILS (Italian Group of Minimally Invasive Liver Surgery) Registry.

Authors:  Giovanni Battista Levi Sandri; Giuseppe Maria Ettorre; Luca Aldrighetti; Umberto Cillo; Raffaele Dalla Valle; Alfredo Guglielmi; Vincenzo Mazzaferro; Alessandro Ferrero; Fabrizio Di Benedetto; Salvatore Gruttadauria; Luciano De Carlis; Giovanni Vennarecci
Journal:  Surg Endosc       Date:  2018-09-10       Impact factor: 4.584

Review 4.  Laparoscopic hepatectomy for elderly patients: Major findings based on a systematic review and meta-analysis.

Authors:  Ke Chen; Yu Pan; Hendi Maher; Bin Zhang; Xue-Yong Zheng
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

5.  Minimally invasive versus open right hepatectomy: comparative study with propensity score matching analysis.

Authors:  Vinícius Campos Duarte; Fabricio Ferreira Coelho; Alain Valverde; Divia Danoussou; Jaime Arthur Pirola Kruger; Kevin Zuber; Gilton Marques Fonseca; Vagner Birk Jeismann; Paulo Herman; Renato Micelli Lupinacci
Journal:  BMC Surg       Date:  2020-10-30       Impact factor: 2.102

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.